Nuclear Medicine Market - Global Forecast 2025-2032

The nuclear medicine market is evolving rapidly, driven by major advances in imaging and radiopharmaceutical therapies. Stakeholders across healthcare, research, and industry are reshaping clinical practices—with transformative implications for diagnostics, treatment, and operational models.

Market Snapshot: Nuclear Medicine Market Overview

The Nuclear Medicine Market grew from USD 14.60 billion in 2024 to USD 16.05 billion in 2025. It is expected to continue growing at a CAGR of 11.08%, reaching USD 33.87 billion by 2032. Market expansion is underpinned by innovations in imaging modalities, radiotherapeutic agents, and data-driven care pathways that enable more personalized and precise interventions.

Scope & Segmentation

This report offers a comprehensive assessment of the global nuclear medicine landscape. It details opportunities and trends across products, technology platforms, applications, end users, and geographies.

• Product Type: Diagnostic radiopharmaceuticals (including PET and SPECT isotopes), therapeutic nuclear medicine solutions, brachytherapy isotopes (such as cesium-131, iodine-125, iridium-192, palladium-103), and radiopharmaceutical therapies using alpha and beta emitters.
• Mode of Administration: Intravenous injection and oral ingestion, both with unique workflow and patient care impacts.
• Usage: Diagnostic procedures (PET and SPECT scanners, with analog and digital PET systems) and therapeutic procedures focusing on targeted radiotherapy.
• Application Areas: Cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics, pulmonology.
• End Users: Academic and research institutes, diagnostic centers, government hospitals, and private hospitals.
• Regional Coverage: Comprehensive analysis across Americas (including United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Company Profiles: Detailed examination of leading players such as 3B Pharmaceuticals GmbH, Actinium Pharmaceuticals, Inc., Bayer AG, Bracco S.p.A., GE HealthCare, Siemens Healthineers AG, Novartis AG, and others, highlighting strategies, product pipelines, and competitive positioning.

Nuclear Medicine Market: Key Takeaways

• Advanced imaging techniques and new radiopharmaceuticals are enhancing clinical accuracy and supporting more tailored patient therapies.
• Integration of diagnostic and therapeutic modalities enables a shift from broad-based treatments to personalized disease management.
• Collaboration across academic institutions, startups, and established industry leaders is accelerating innovation and shortening development timelines.
• Artificial intelligence is improving workflow automation, image interpretation, and real-time decision support for clinicians.
• Operational resilience strategies are critical as organizations respond to shifting regulatory requirements and evolving reimbursement models.

Tariff Impact and Operational Adjustments

Recent tariff adjustments in the United States are influencing procurement and cost structures for nuclear medicine suppliers and distributors. Increased duties on critical isotopes and imaging components are prompting stakeholders to explore new sourcing options and invest in domestic as well as regional production. Regulatory compliance has been elevated as a key focus to ensure uninterrupted supply of essential radiopharmaceuticals. Stakeholders are prioritizing efficiency, quality assurance, and robust inventory management to address these challenges.

Methodology & Data Sources

This analysis uses a rigorous research approach combining in-depth interviews with key opinion leaders, decision-makers at imaging and radiopharmaceutical companies, and relevant clinical practitioners. Secondary research draws on peer-reviewed journals, clinical trial data, patent sources, and leading market databases. Comprehensive validation ensures reliable findings and actionable insights for market participants.

Why This Report Matters

• Offers a granular understanding of nuclear medicine market segmentation and regional trends to support strategic investments and partnerships.
• Delivers actionable intelligence on emerging technologies and evolving clinical pathways for decision-makers targeting growth and operational improvement.
• Provides clarity on tariff-induced supply chain and regulatory implications, informing robust risk mitigation and long-term planning.

Conclusion

Nuclear medicine stands at a pivotal juncture, shaped by innovation, evolving regulations, and shifting market demands. Senior leaders using these insights can refine their growth strategies and navigate the sector’s complexity with greater confidence and clarity.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.